Terms: = Brain cancer AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2
103 results:
1. Central neurocytoma exhibits radial glial cell signatures with fgfr3 hypomethylation and overexpression.
Lee Y; Chowdhury T; Kim S; Yu HJ; Kim KM; Kang H; Kim MS; Kim JW; Kim YH; Ji SY; Hwang K; Han JH; Hwang J; Yoo SK; Lee KS; Choe G; Won JK; Park SH; Lee YK; Shin JH; Park CK; Kim CY; Kim JI
Exp Mol Med; 2024 Apr; 56(4):975-986. PubMed ID: 38609519
[TBL] [Abstract] [Full Text] [Related]
2. Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients.
Stepien N; Mayr L; Schmook MT; Raimann A; Dorfer C; Peyrl A; Azizi AA; Schramm K; Haberler C; Gojo J
Pediatr Blood Cancer; 2024 Mar; 71(3):e30836. PubMed ID: 38177074
[TBL] [Abstract] [Full Text] [Related]
3. Systematic review and cumulative analysis of clinical properties of BRAF V600E mutations in PLNTY histological samples.
Baumgartner ME; Lang SS; Tucker AM; Madsen PJ; Storm PB; Kennedy BC
Childs Nerv Syst; 2024 May; 40(5):1361-1366. PubMed ID: 38150037
[TBL] [Abstract] [Full Text] [Related]
4. Clinical significance of molecular subgroups of polymorphous low-grade neuroepithelial tumor of the young (PLNTY): A small single institutional case series and integrated analysis.
Vuong HG; Alzayadneh E; Reith TP; Eschbacher KL
Pathol Res Pract; 2023 Dec; 252():154922. PubMed ID: 37984047
[TBL] [Abstract] [Full Text] [Related]
5. Licochalcone A: A Potential Multitarget Drug for Alzheimer's Disease Treatment.
Olloquequi J; Ettcheto M; Cano A; Fortuna A; Bicker J; Sánchez-Lopez E; Paz C; Ureña J; Verdaguer E; Auladell C; Camins A
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762479
[TBL] [Abstract] [Full Text] [Related]
6. A diffuse glioma with oligodendroglial-like cells and extensive calcifications.
Martelli FM; Marastoni E; Barresi V
Brain Pathol; 2024 Jan; 34(1):e13187. PubMed ID: 37409721
[TBL] [Abstract] [Full Text] [Related]
7. Structural basis for FGF hormone signalling.
Chen L; Fu L; Sun J; Huang Z; Fang M; Zinkle A; Liu X; Lu J; Pan Z; Wang Y; Liang G; Li X; Chen G; Mohammadi M
Nature; 2023 Jun; 618(7966):862-870. PubMed ID: 37286607
[TBL] [Abstract] [Full Text] [Related]
8. Elucidating the potential effects of point mutations on fgfr3 inhibitor resistance via combined molecular dynamics simulation and community network analysis.
Liu B; Ding J; Liu Y; Wu J; Wu X; Chen Q; Li W
J Comput Aided Mol Des; 2023 Jul; 37(7):325-338. PubMed ID: 37269435
[TBL] [Abstract] [Full Text] [Related]
9. Epigenetic Alteration of H3K27me3 as a Possible Oncogenic Mechanism of Central Neurocytoma.
Kim H; Lee K; Shim YM; Kim EE; Kim SK; Phi JH; Park CK; Choi SH; Park SH
Lab Invest; 2023 Aug; 103(8):100159. PubMed ID: 37088465
[TBL] [Abstract] [Full Text] [Related]
10. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with fgfr3::TACC3 fusion.
Métais A; Tauziède-Espariat A; Garcia J; Appay R; Uro-Coste E; Meyronet D; Maurage CA; Vandenbos F; Rigau V; Chiforeanu DC; Pallud J; Senova S; Saffroy R; Colin C; Edjlali M; Varlet P; Figarella-Branger D;
Acta Neuropathol Commun; 2023 Jan; 11(1):14. PubMed ID: 36647073
[TBL] [Abstract] [Full Text] [Related]
11. Lung cancer presenting with central nervous system metastasis: Clinicopathological and molecular analysis of 171 cases.
Demleitner M; Erlenbach-Wünsch K; Coras R; Erber R; Polifka I; Eyüpoğlu I; Fuchs F; Hartmann A; Agaimy A
Ann Diagn Pathol; 2023 Apr; 63():152082. PubMed ID: 36634550
[TBL] [Abstract] [Full Text] [Related]
12. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
[TBL] [Abstract] [Full Text] [Related]
13. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood cancer.
Lazo De La Vega L; Comeau H; Sallan S; Al-Ibraheemi A; Gupta H; Li YY; Tsai HK; Kang W; Ward A; Church AJ; Kim A; Pinto NR; Macy ME; Maese LD; Sabnis AJ; Cherniack AD; Lindeman NI; Anderson ME; Cooney TM; Yeo KK; Reaman GH; DuBois SG; Collins NB; Johnson BE; Janeway KA; Forrest SJ
JCO Precis Oncol; 2022 Nov; 6():e2200390. PubMed ID: 36446043
[TBL] [Abstract] [Full Text] [Related]
14. Piperazine derivatives with potent drug moiety as efficient acetylcholinesterase, butyrylcholinesterase, and glutathione S-transferase inhibitors.
Karaytuğ MO; Balcı N; Türkan F; Gürbüz M; Demirkol ME; Namlı Z; Tamam L; Gülçin İ
J Biochem Mol Toxicol; 2023 Feb; 37(2):e23259. PubMed ID: 36419212
[TBL] [Abstract] [Full Text] [Related]
15. Identification of upregulated genes in glioblastoma and glioblastoma cancer stem cells using bioinformatics analysis.
Caglar HO; Duzgun Z
Gene; 2023 Jan; 848():146895. PubMed ID: 36122609
[TBL] [Abstract] [Full Text] [Related]
16. Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.
Shafi O; Siddiqui G
World J Surg Oncol; 2022 May; 20(1):146. PubMed ID: 35538578
[TBL] [Abstract] [Full Text] [Related]
17. Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics.
Vagvala S; Guenette JP; Jaimes C; Huang RY
Cancer Imaging; 2022 Apr; 22(1):19. PubMed ID: 35436952
[TBL] [Abstract] [Full Text] [Related]
18. Identification of Pyridinyltriazine Derivatives as Potent panFGFR Inhibitors against Gatekeeper Mutants for Overcoming Drug Resistance.
Ryu S; Nam Y; Kim N; Shin I; Jeon E; Kim Y; Kim ND; Sim T
J Med Chem; 2022 Apr; 65(8):6017-6038. PubMed ID: 35436119
[TBL] [Abstract] [Full Text] [Related]
19. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Lassman AB; Sepúlveda-Sánchez JM; Cloughesy TF; Gil-Gil MJ; Puduvalli VK; Raizer JJ; De Vos FYF; Wen PY; Butowski NA; Clement PMJ; Groves MD; Belda-Iniesta C; Giglio P; Soifer HS; Rowsey S; Xu C; Avogadri F; Wei G; Moran S; Roth P
Clin Cancer Res; 2022 Jun; 28(11):2270-2277. PubMed ID: 35344029
[TBL] [Abstract] [Full Text] [Related]
20. Discovery of ASP5878: Synthesis and structure-activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity.
Kuriwaki I; Kameda M; Iikubo K; Hisamichi H; Kawamoto Y; Kikuchi S; Moritomo H; Terasaka T; Iwai Y; Noda A; Tomiyama H; Kikuchi A; Hirano M
Bioorg Med Chem; 2022 Apr; 59():116657. PubMed ID: 35219181
[TBL] [Abstract] [Full Text] [Related]
[Next]
